Plant Health Care plc

DB:PC5 Stock Report

Market Cap: €35.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Plant Health Care Valuation

Is PC5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PC5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PC5 (€0.1) is trading below our estimate of fair value (€0.28)

Significantly Below Fair Value: PC5 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PC5?

Key metric: As PC5 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PC5. This is calculated by dividing PC5's market cap by their current revenue.
What is PC5's PS Ratio?
PS Ratio3.5x
SalesUS$11.21m
Market CapUS$39.75m

Price to Sales Ratio vs Peers

How does PC5's PS Ratio compare to its peers?

The above table shows the PS ratio for PC5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
BNN BRAIN Biotech
1.2x8.5%€69.9m
SDF K+S
0.5x0.4%€2.0b
IBU IBU-tec advanced materials
0.6x19.2%€27.4m
DLX Delignit
0.3x10.2%€23.8m
PC5 Plant Health Care
3.5x35.8%€30.5m

Price-To-Sales vs Peers: PC5 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does PC5's PS Ratio compare vs other companies in the European Chemicals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
PC5 3.5xIndustry Avg. 1.0xNo. of Companies31PS01.22.43.64.86+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PC5 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the European Chemicals industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is PC5's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PC5 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: PC5 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Compañía de Minas BuenaventuraA

US$3.1b

Engages in the exploration, development, construction, and operation of mineral processing business.

MBU

US$11.70

7D

0%

1Y

35.3%

Mitsubishi Chemical Group

JP¥1.1t

Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.

M3C

JP¥4.80

7D

-4.0%

1Y

-17.0%

Cabka

€59.3m

Manufactures and sells pallets and large containers made from recycled plastic in Europe, North America, and internationally.

7GW

€2.34

7D

-12.7%

1Y

-61.8%